Evidence of EZH2 dependent and independent mechanisms of tazemetostat treatment emergent resistance in models of diffuse large B cell lymphoma

被引：0
作者：
Campbell, Carly T.
Jasper, Jeff S.
Daigle, Scott R.
Ribich, Scott A.
Keilhack, Heike
Smith, Jesse S.
Ho, Peter T.
Blakemore, Stephen J.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
312
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Treatment of diffuse large B-cell lymphoma
    Gleissner, B.
    Zwick, C.
    Pfreundschuh, M.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2008, 133 (36) : 1785 - 1794
  • [42] Treatment of Diffuse Large B-Cell Lymphoma
    Miyazaki, Kana
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2016, 56 (02) : 79 - 88
  • [43] ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma
    Diaz-Chavez, Jose
    Gutierrez-Hernandez, Olga
    Taja-Chayeb, Lucia
    Gutierrez-Chavarria, Sindy
    Aviles-Salas, Alejandro
    Candelaria, Myrna
    CANCERS, 2022, 14 (19)
  • [44] Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma
    Ennishi, Daisuke
    Takata, Katsuyoshi
    Beguelin, Wendy
    Duns, Gerben
    Mottok, Anja
    Farinha, Pedro
    Bashashati, Ali
    Scott, David
    Boyle, Merrill
    Meissner, Barbara
    Ben-Neriah, Susana
    Woolcock, Bruce W.
    Telenius, Adele
    Lai, Daniel
    Teater, Matthew R.
    Kridel, Robert
    Savage, Kerry J.
    Sehn, Laurie H.
    Morin, Ryan D.
    Marra, Marco A.
    Shah, Sohrab P.
    Connors, Joseph M.
    Gascoyne, Randy D.
    Scott, David W.
    Melnick, Ari M.
    Steidl, Christian
    BLOOD, 2018, 132
  • [45] Morphoproteomics Identifies SIRT1, EZH2 and CXCR4 Pathways in Diffuse Large B-Cell Lymphoma: Therapeutic Implications
    Brown, Robert E.
    Zhang, Songlin
    Wang, Xiaohong I.
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2022, 52 (01) : 27 - 32
  • [46] Mechanisms of Sensitivity and Resistance to Histone Deacetylase Inhibitors in Diffuse Large B-Cell Lymphoma
    Tula-Sanchez, Ana A.
    Havas, Aaron
    Alonge, Peter
    Klein, Mary E.
    Rogers, Taralyn Y.
    Szeto, Emily
    Rimsza, Lisa M.
    Smith, Catharine L.
    BLOOD, 2012, 120 (21)
  • [47] Targeting DNA Repair Mechanisms to Overcome Drug Resistance in Diffuse Large B Cell Lymphoma
    Devin, Julie
    Lin, Yea-Lih
    Kassambara, Alboukadel
    Cartron, Guillaume
    Elemento, Olivier
    Constantinou, Angelos
    Pasero, Philippe
    Bret, Caroline
    Moreaux, Jerome
    BLOOD, 2017, 130
  • [48] Drug resistance in diffuse large B-cell lymphoma
    Wilson, Wyndham H.
    SEMINARS IN HEMATOLOGY, 2006, 43 (04) : 230 - 239
  • [49] Prognostic models for diffuse large B-cell lymphoma
    Conconi, A
    Zucca, E
    Roggero, E
    Bertoni, F
    Bernasconi, A
    Mingrone, W
    Pedrinis, E
    Cavalli, F
    HEMATOLOGICAL ONCOLOGY, 2000, 18 (02) : 61 - 73
  • [50] Infection is an Independent Predictor of Death in Diffuse Large B Cell Lymphoma
    Claire Dendle
    Michael Gilbertson
    Tim Spelman
    Rhonda L. Stuart
    Tony M. Korman
    Karin Thursky
    Stephen Opat
    Zoe McQuilten
    Scientific Reports, 7
12345